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Abstract
Background: The UK, like other developed countries, is experiencing a marked change in the age
structure of its population characterised by increasing life expectancy and continuing growth in the
older fraction of the population. There is remarkably little up-to-date information about the health
of the oldest old (over 85 years), demographically the fastest growing section of the population.
There is a need, from both a policy and scientific perspective, to describe in detail the health status
of this population and the factors that influence individual health trajectories. For a very large
proportion of medical conditions, age is the single largest risk factor. Gaining new knowledge about
why aged cells and tissues are more vulnerable to pathology is likely to catalyse radical new insights
and opportunities to intervene. The aims of the Newcastle 85+ Study are to expose the spectrum
of health within an inception cohort of 800 85 year-olds; to examine health trajectories and
outcomes as the cohort ages and their associations with underlying biological, medical and social
factors; and to advance understanding of the biological nature of ageing.
Methods: A cohort of 800 85 year olds from Newcastle and North Tyneside will be recruited at
baseline and followed until the last participant has died. Eligible individuals will be all those who turn
85 during the year 2006 (i.e. born in 1921) and who are registered with a Newcastle or North
Tyneside general practice. Participants will be visited in their current residence (own home or
institution) by a research nurse at baseline, 18 months and 36 months. The assessment protocol
entails a detailed multi-dimensional health assessment together with review of general practice
medical records. Participants will be flagged with the NHS Central Register to provide details of
the date and cause of death.
Discussion:  The Newcastle 85+ Study will address key questions about health and health-
maintenance in the 85+ population, with a particular focus on quantitative assessment of factors
underlying variability in health, and on the relationships between health, nutrition and biological
markers of the fundamental processes of ageing.
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Background
The UK, like other developed countries, is experiencing a
marked change in the age structure of its population, char-
acterised by increasing life expectancy and continuing
growth in the older fraction of the population [1-4]. Con-
trary to all major forecasts by national and international
agencies over the last few decades, life expectancy has not
reached a plateau but has continued to increase by about
two years per decade [5-7]. In addition to the obvious rea-
sons for the priority assigned to improving the health and
care of older people within the UK through activities such
as the NHS Strategic Review of Ageing and Age-Associated
Disease and Disability [8] and the National Service Frame-
work for Older People [9], there is great scientific interest
in studying in detail what is happening to the health of
the oldest old (over 85 years) and the factors that influence
individual health trajectories. These insights are impor-
tant, not only to inform us about the health status of what
is demographically the fastest growing section of the pop-
ulation (about whom there is remarkably little up-to-date
information), but also for what they will tell us about the
ageing process itself and the factors that affect it. For a very
large proportion of medical conditions, age is the single
largest risk factor. Gaining new knowledge about why
aged cells and tissues are more vulnerable to pathology is
likely to catalyse radical new insights and opportunities to
intervene. The rapidly declining mortality rates of the very
old point to much greater intrinsic malleability in the
mechanisms of ageing than has hitherto been appreciated.
This fits well with new biological understanding of ageing,
which has been led to a significant extent by our own pre-
vious research [10-15]; ageing is not programmed but
results from a gradual, lifelong accumulation of subtle
damage in the cells and tissues of the body over time. This
is modulated by genetic factors, chiefly those involved in
maintenance and repair (e.g. DNA repair, antioxidant
defences). However, the process appears to be susceptible
to a wide range of non-genetic factors, particularly nutri-
tion and lifestyle, which in turn may be affected by socio-
economic status. Genes account for about 25% of the
variability of human longevity [16], and the remaining
75% is believed to be due to factors such as nutrition, life-
style, and socioeconomic variables, but as yet these have
not been determined with any precision. This biological
understanding is important for the emphasis it places on
the life-course nature of the ageing process and its amena-
bility to positive interventions. A striking feature of bio-
logical ageing is its marked variability between
individuals [17-22]. This is particularly evident among the
oldest old where some individuals preserve strikingly high
levels of health and functional ability. Understanding the
sources of variability in the oldest-old phenotype will be
essential to identify factors contributing to malleability of
the ageing process.
Very few measures of health status have been applied sys-
tematically within the 85+ age group in the UK [23-25]
and no study has yet attempted a comprehensive assess-
ment of biological, medical and social characteristics. The
MRC Trial of Assessment and Management of Older Peo-
ple in the Community compared different methods of
screening and management of older people, excluding
those in long stay hospitals and care homes [26-30]. This
mainly cross-sectional trial provided valuable baseline
health information on 33,000 75+ year olds, including
5000 in the 85+ age group, with some follow-up for mor-
tality and hospital/institutional admissions. Tinker et al
[31], in an analysis of national survey data from the
1990s, compared the housing, general health and care use
of people in the 85+ age group to those aged 65–84. The
importance of socioeconomic factors for health of those
still in employment was shown by the Whitehall Study
[32]. The English Longitudinal Study on Ageing [33] is
focusing on interactions between health and socioeco-
nomic status in 11,000 individuals across a broader age
range from 50 to 80+; however the information on the
oldest old is relatively scarce with only 250 participants
aged 85 and over at baseline and potential bias due to the
sampling method used. Other previous studies relevant to
understanding health among the very old are the MRC
Cognitive Function and Ageing Study (CFAS) [34,35] and
the Leiden 85+ Study [36,37]. CFAS is a population-based
study, in six centres in England and Wales (including
Newcastle), of people aged 65 or over living in the com-
munity, including long-term care institutions. It is a lon-
gitudinal study of 13,004 participants sampled in 1990,
with the most recent follow up completed in 2003. At
baseline, 1508 participants were aged 85 and over. The
core aim of CFAS has been to estimate the prevalence and
incidence of cognitive impairment and dementia. The
most direct investigation of the overall health status of the
very old is the Leiden 85+ Study which recruited 599 indi-
viduals aged 85 in 1997 (response rate 87%) and fol-
lowed them, with annual visits, for five years. The Leiden
study included measures on a range of health variables,
with a particular focus on inflammation and vascular fac-
tors.
The Newcastle 85+ Study design has been developed and
fully tested during a cross-sectional study of 85 year olds
from four Newcastle general practices which was con-
ducted in 2003–2004. Eighty-nine individuals were
recruited to the full study (66% of those eligible) with an
additional 27 (20% of those eligible) agreeing to review of
general practice medical records only. The results and
experience of this study helped shape the detailed plans
for the main project. Extensive consultation has taken
place with local consumer groups together with other
stakeholders such as the local primary care trusts, general
practitioners, community nursing staff, social services andBMC Geriatrics 2007, 7:14 http://www.biomedcentral.com/1471-2318/7/14
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care home managers. Close links have also been estab-
lished with local media which will be used to publicise the
study.
The Newcastle 85+ Study is designed using experience
from the pilot study, from the Leiden group, with whom
we have close collaboration, and with expertise gained
within MRC CFAS. The Newcastle study will address key
questions about health and health-maintenance in the
85+ population, with a particular focus on quantitative
assessment of factors underlying variability in health and
on the relationships between health, nutrition and bio-
logical markers of fundamental processes of ageing. It will
include a range of important questions not included in
the Leiden study, particularly with respect to detailed
analyses of nutrition and biological markers of ageing.
Aims
The aims of the Newcastle 85+ Study are to:
i). Expose the spectrum of health within an inception
cohort of 800 85 year-olds, selected without regard to
health status as far as is possible, establishing the distribu-
tions (especially the variability) of a broad range of health
measures within the group.
ii). Examine, in unprecedented detail, health trajectories
and outcomes as the cohort ages and their associations
with underlying biological, medical and social factors.
This longitudinal element will focus on factors contribut-
ing to maintenance of health in this age group and assess
the predictive value of biological and other markers of
health as measured at baseline.
iii). Advance understanding of the biological nature of
ageing.
Methods
A cohort of 800 85 year olds from Newcastle and North
Tyneside will be recruited at baseline and followed until
the last participant has died. The UK Medical Research
Council, together with the Biotechnology and Biological
Sciences Research Council, has provided funding for the
first 5 years of the project. Ethical approval has been
obtained from Newcastle & North Tyneside Local
Research Ethics Committee. The first 5 years are divided
into 4 stages as illustrated in Figure 1. The stages have
been designed to maximise the length of follow-up whilst
allowing key results to be obtained during the funded
period.
Stage 0: Staff training and piloting of assessment 
instruments (1 month)
Stage 1: Baseline recruitment and assessment (18 months 
duration)
Recruitment
The cohort will be recruited from general practices in
Newcastle and North Tyneside Primary Care Trusts. Eligi-
ble individuals will be all those who turn 85 during the
year 2006 (i.e. born in 1921) and who are registered with
any Newcastle or North Tyneside Primary Care Trust gen-
eral practice. All individuals who meet these inclusion cri-
teria will be invited to participate, whether living at home
or in an institution, and regardless of their state of health
(except for exclusion by their general practitioner (GP)
due to end stage terminal illness). Potential participants
will be identified through the primary care trusts' GP
patient lists and we will liaise with GPs to cross-check
these lists (to exclude recent deaths and the terminally ill)
and to request a 'letter of support'.
The study team will send each potential participant a letter
of invitation together with an information pack, photo-
graphs of those research staff involved in home visits and
a 'letter of support' from their GP. The letter of invitation
will be followed after one week by a telephone call or
home visit from a research nurse to discuss the study in
more detail. Previous experience in similar studies involv-
ing very old people has shown that direct telephone con-
tact or visiting are the only reliable ways of finding out
whether individuals are interested in participating in
research. As many very old people are frail, they may find
posting reply slips or making the first telephone call them-
selves too much of a burden. No pressure is put on the
person to participate; this procedure has been adopted
Gant chart of the Newcastle 85+ Study timelines Figure 1
Gant chart of the Newcastle 85+ Study timelines.
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purely as a way of ensuring the older person receives all
the relevant information to enable them to make an
informed decision about participation. Once an individ-
ual has shown an interest in participating, an appoint-
ment is made to visit them in their own home. The
purpose of this visit is to ensure that they have received
and understand the study information and the implica-
tions of their involvement. If they wish to participate,
written informed consent is then obtained.
As around 15% [34] of the proposed sample may have sig-
nificant cognitive impairment, due consideration has
been given to the ethical issues this raises. It is important
not to exclude such people from scientific research as, so
doing, could prevent this group from benefiting from
advances in medical understanding. However there is a
need to carefully consider the consent process. The Mental
Capacity Act 2005 provides a statutory framework 'to
empower and protect vulnerable people who may not be
able to make their own decisions' [38]. At the forefront of
this framework is the principle that capacity of an individ-
ual to consent must be assumed unless it is proved other-
wise. During the first visit to a potential participant, the
research nurse will establish their level of capacity utilis-
ing a consent checklist and consent pathway, based upon
information from the individual, family and significant
others. Each participant will be asked to give consent
appropriate to their level of understanding ranging from
written full informed consent to verbal or non-verbal
communication, of which account will be taken in deter-
mining willingness to participate. In those individuals
found to be without capacity to give full informed con-
sent, proxy assent/consultee approval will also be sought
from a close relative or, in those potential participants
without relatives, from an immediate carer. They will be
asked to use their knowledge of the participant, in the past
and the present, and will be required to state that, in their
opinion, the participant would have had no objection to
entering the study when cognitively intact, and would not
be caused undue distress by participation. The consent
protocol incorporates the notion that consent is a process
and as such requires ongoing confirmation prior to and
within each contact. If a participant is found to have lost
capacity during the course of the study, consent is not
deemed as being enduring and a process of gaining proxy
assent/consultee approval is initiated, whilst suspending
all contacts.
Assessment
Participants will be visited in their current residence (own
home or institution) by a research nurse. If a potential
participant is temporarily in hospital at the time of recruit-
ment (1% of those eligible to participate in the pilot
study), assessment will be deferred until discharge. Home
based assessment is vital for high recruitment levels in this
age group; in our pilot study over half of the sample
would have been unwilling to attend hospital for assess-
ment.
The baseline assessment protocol entails a detailed multi-
dimensional health assessment by means of:
a). Questionnaires: socio-economic status; family data;
physical health (global health status, longstanding illness,
angina, shortness of breath, falls, generalised pain, joint
pain, fractures, incontinence, vision and hearing); psycho-
logical health (depression); disability; diet; oral health;
lifestyle (smoking, alcohol and exercise); social support
and participation; use of health and social care.
b). Measurements and function tests: weight, bio-imped-
ance (body composition-fat and water), demi-span, waist
and hip circumference, tooth count, blood pressure,
hand-grip strength, walking test (timed 'up and go' test),
cognitive function (mini-mental state examination and
computerised assessment of memory and attention (CDR
battery)), electrocardiogram, spirometry and oximetry.
c). Blood tests: blood samples, taken after an overnight
fast where possible, will be analysed for:
1. Routine haematology and biochemistry: full blood count;
creatinine and electrolytes; liver panel; bone panel; glu-
cose; glycosylated haemoglobin.
2.  Lipid profile: cholesterol, triglycerides, high and low
density lipoproteins, apolipoproteins (A1 and B).
3. Thyroid function: free T4, free T3, reverse T3, TSH and
TPO antibodies.
4. Inflammatory markers: High sensitivity CRP, rheumatoid
factor, cytokines (TNF-alpha and Interleukin 6).
5. Cortisol
6. Nutritional markers: Vitamins B2, B6, B12, C and D, fer-
ritin, red cell folate and homocysteine.
7. Biomarkers: DNA repair capacity, telomere length, F2-
isoprostane (marker of oxidative stress).
8. Markers of immunosenescence: T cell oligoclonality and
lymphocyte subpopulation distributions (senescent T-
cells, memory T-cells and NKcells).
In addition, DNA, RNA and plasma will be stored for
future analyses (including genetic, proteomic, metabo-
lomic and allostatic load markers concerned with ageing
[39]).BMC Geriatrics 2007, 7:14 http://www.biomedcentral.com/1471-2318/7/14
Page 5 of 7
(page number not for citation purposes)
Information will be gathered during three nurse visits
each lasting about one hour and 30 minutes and one
additional nurse visit to collect the fasting blood samples;
visits to individual participants will take place over one
month. Data will be entered directly onto a tablet style
laptop computer. For those participants who are particu-
larly frail, there will be the option to spread the assess-
ments over more visits, to have a shorter assessment in
total and for much of the interview to be conducted with
an 'informant' i.e. a relative/carer who knows the partici-
pant well. With participants' consent, their GP will be
informed about their participation and of any abnormal
assessment findings of immediate clinical relevance. In
addition participants' GP records will be reviewed for
information on medication, key diagnoses and use of GP
services. For those individuals who decline to participate
in the full assessment, there will be the option to consent
to review of records only.
The full protocol was tested during the pilot study and
shown to be fully practical and practicable. The schedule
was shown to be acceptable to participants; 96% rated
their involvement in the study as positive or very positive
and 93% of those recruited completed all the nurse visits.
Safety issues have been addressed; research nurses will
have enhanced Criminal Records Bureau clearance and
carry photo-identification on visits, participants will be
sent photographs of the research team with their invita-
tion letter and local police will be informed about the
study. For staff safety, the location of staff involved in
community visits will be monitored using an automated
telephone call-back system.
It will not be possible to check inter-rater reliability for
home assessment data collection due to the participant
interview burden this would entail. However reliability of
the data extraction from GP records will be examined in a
core set of variables which cover the range of difficulty and
modes of extraction from GP records. From the pilot data,
where 3 individuals extracted data independently from
the same GP records, we found the intraclass correlation
coefficient (ICC) to vary from 0.55 for number of heart
attacks to 0.99 for number of consultations. We estimate
therefore that 9 nurses extracting information from the
same set of 32 notes will have 80% power with a type I
error rate of 5% to show at least moderate agreement
(ICC>0.4) for the majority of variables extracted.
Stages 2 and 3: Follow-up assessments at 18 months and 36 
months (each of 18 months duration)
It is anticipated that 9–13% of the cohort will die per year
with additional cohort loss due to drop out of 5–10% per
year (Gussekloo, J. 2004, personal communication);
increasing age is a key predictor of attrition (and non-
response) in population studies of older people [40]. Par-
ticipants will be flagged with the NHS Central Register to
provide details of the date and cause of death. Survivors
will be revisited in Stage 2 (18 months from baseline) and
Stage 3 (36 months from baseline). The exact detail of the
assessments to be conducted at follow-up has yet to be
decided. It is envisaged that there will be a core assessment
comprising:
a). Questionnaires: changes in living arrangements, phys-
ical health, psychological health, disability, lifestyle,
social support and participation and use of health and
social care.
b). Measurements and function tests: weight, blood pres-
sure, hand-grip strength, walking test and cognitive func-
tion.
c). Blood samples: routine haematology and biochemis-
try; lipid profile; inflammatory markers; biomarkers of
ageing (telomere length, oxidative stress, immunosense-
cence) and storage of samples for future analyses (RNA,
proteomics, metabolomics and allostatic load markers).
A repeat review of GP records will be conducted in Stage 3
to obtain information on key medical events occurring
during the follow-up period. In addition, additional fund-
ing will be sought to allow further key domains of health
to be addressed in more detail including nutrition, oral
health, cardiac disease and musculoskeletal disease.
Sample size considerations
Since there are a large number of specific factors to be ana-
lysed, formal sample size calculations for the study as a
whole were not feasible.
The number was decided upon from the following consid-
erations:
(i) A previous study of similar design (Leiden 85+ Study)
had 599 participants, which proved sufficient for a range
of important, statistically significant conclusions to be
drawn. We have increased this by one third.
(ii) Based on the pilot study, this is the number we can
expect to recruit from those turning 85 within a single year
inside a study area of manageable extent, taking account
of the need to return blood samples within a defined short
window of time for some of the laboratory analyses.
(iii) Statistical calculations indicated that, based on data
from the pilot study, this sample size will deliver appro-
priately precise estimates of the main effects within major
sub-groups.BMC Geriatrics 2007, 7:14 http://www.biomedcentral.com/1471-2318/7/14
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Stage 4: Data analysis
Interim analyses will take place after the completion of
each phase. In Stage 4, full analysis of the data will be con-
ducted using multi-variate statistical methods and incor-
porating systems biology modelling approaches which
make use of advanced mathematical and computational
techniques.
Discussion
The Newcastle 85+ Study will address key questions about
health and health-maintenance in the 85+ population,
with a particular focus on quantitative assessment of fac-
tors underlying variability in health, and on the relation-
ships between health, nutrition and biological markers of
the fundamental processes of ageing. Given the age of the
participants, we expect significant morbidity and mortal-
ity among the cohort (life expectancy at age 85 is 5 years
for men and 6 years for women [41]) and we will be able
to analyse how these various outcomes can be related to
measures recorded at baseline and during follow-up. One
of the main objectives of the study is to identify factors
associated with the different health trajectories followed
by individuals after age 85. There is pronounced variabil-
ity in individual ageing trajectories for reasons which are
at present poorly understood. By conducting regular fol-
low-ups we will be able to identify the variability in indi-
vidual health trajectories within the cohort and to
examine their associations with biological and other fac-
tors. The focus will be on factors involved in the mainte-
nance of health among those who have already attained
age 85, not on those affecting survival to 85. Although the
latter is of great interest, extensive data already exist on
factors influencing morbidity and mortality in middle
and young-old age groups, whereas there are hardly any
data on health maintenance among the oldest old. Given
the rapid increase in this age group and their risk of high
dependency, identification of factors that can maintain
healthy, independent living are of primary interest in their
own right, quite apart from what they can tell us about the
ageing process.
To address the full complexity of genetic and non-genetic
factors affecting healthy ageing across the full range of
geographical and ethnic diversity within the UK would be
prohibitively extensive and expensive. We have chosen a
single age at recruitment and a single geographical region
in order to capture as clear a picture as possible of the fac-
tors explaining variability within  this cohort. If we can
clearly identify factors associated with maintenance of
health in 85-year old Newcastle/North Tyneside residents,
not only will this help us to understand the interplay of
such factors with underlying processes of ageing them-
selves, but it is highly likely that the actions of such factors
will play out in similar ways in other populations. This
can be verified and future studies streamlined using the
Newcastle 85+ Study as a reference point. A particular
benefit of the population in North East England is that it
shows exceptional genetic and social stability, while also
covering all socioeconomic groups.
We recognise that what we are proposing is different from
the hypothesis-driven approach that has characterised
most epidemiological and clinical trial work to date, yet
we are firmly convinced that such an approach is not only
timely but necessary to begin to answer some fundamen-
tally important questions about the ageing process, which
will have major long-term relevance for public health not
only of the oldest old. In effect, what we propose is a sys-
tems-biology approach to human ageing. Many areas of
the life sciences, including biomedicine, are moving
towards recognition that such approaches, which are char-
acterised by using data to develop predictive models that
contribute new information and suggest hypotheses for
further tests, are essential to understand complex phe-
nomena.
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